Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 plus paclitaxel as second-line treatment for small cell lung cancer
ChiCTR2200059911Phase 2Not yet recruiting
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- Mar 2022
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of pumitamig and paclitaxel in small cell lung cancer (SCLC), sponsored by Jilin Provincial Cancer Hospital. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
pumitamigpaclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2200059911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059911.